147 related articles for article (PubMed ID: 31396953)
1. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
Galaine J; Turco C; Vauchy C; Royer B; Mercier-Letondal P; Queiroz L; Loyon R; Mouget V; Boidot R; Laheurte C; Lakkis Z; Jary M; Adotévi O; Borg C; Godet Y
Int J Cancer; 2019 Dec; 145(11):3112-3125. PubMed ID: 31396953
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
3. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
4. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
[TBL] [Abstract][Full Text] [Related]
5. Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.
Loyon R; Jary M; Salomé B; Gomez-Cadena A; Galaine J; Kroemer M; Romero P; Trabanelli S; Adotévi O; Borg C; Jandus C
Front Immunol; 2019; 10():2121. PubMed ID: 31555301
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
9. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
Ghanbarian M; Afgar A; Yadegarazari R; Najafi R; Teimoori-Toolabi L
Biomed Pharmacother; 2018 Dec; 108():1070-1080. PubMed ID: 30372807
[TBL] [Abstract][Full Text] [Related]
10. Thioredoxin domain-containing protein 9 (TXNDC9) contributes to oxaliplatin resistance through regulation of autophagy-apoptosis in colorectal adenocarcinoma.
Zhou W; Fang C; Zhang L; Wang Q; Li D; Zhu D
Biochem Biophys Res Commun; 2020 Apr; 524(3):582-588. PubMed ID: 32029274
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
[TBL] [Abstract][Full Text] [Related]
12. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Maccalli C; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
Cancer Res; 2003 Oct; 63(20):6735-43. PubMed ID: 14583468
[TBL] [Abstract][Full Text] [Related]
13. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
14. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
16. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Hu J; Cai G; Xu Y; Cai S
Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
[TBL] [Abstract][Full Text] [Related]
17. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
[TBL] [Abstract][Full Text] [Related]
19. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
